ENEDYM
25.8.2021 11:32:09 CEST | Business Wire | Press release
Enedym Inc. ( “Enedym”), the technology company that develops next generation switched reluctance motors (SRMs), electric propulsion, and electrified powertrains, announced today that it formed a partnership with the Napino Group. (“Napino”), one of India's leading suppliers of automotive electronic products. Under the terms of the partnership, Napino will license Enedym’s switched reluctance motor (SRM) technology for use in 2-wheel electric motorcycles and scooters in India.
Dr. Ali Emadi, Founder, President, and CEO of Enedym commented, “We are excited to announce this deal with Napino. The partnership between Enedym and Napino is transformative and significant given it will provide a more stable and secure global manufacturing supply chain, combined with sustainable next generation motor technology. The landscape of the automotive industry is changing rapidly and we are excited to provide next generation electric motor technology that aligns with the needs of leading OEMs. Through the use of Enedym’s SRMs – which eliminate the need for rare earth metals often sourced exclusively from China – we are providing a gateway to low cost/high quality manufacturing of next generation motors, inverters, and controllers.
Dr. Emadi added, “We are in the midst of a historic shift, both in terms of electrification, focus on sustainability, and the need for secure and stable supply chains. Partnering with Napino will allow us to supply our next generation motor technology within a massive market and offer Indian based and global OEM’s a viable manufacturing alternative to China.”
Mr. Vaibhav Raheja, Joint Managing Director of Napino commented, “We are extremely delighted to announce our partnership with Enedym. Achieving removal of magnets and rare earth elements in these products offers great advantages not only from a geo-political point of view, but also ensures sensible use of natural resources. We are confident that the affordable and robust solution being created by our engineering & manufacturing teams will offer quicker adoption of electric mobility in India. Our vision is to make India a global manufacturing hub for EV motors and contribute towards making it carbon neutral.”
Commenting on the partnership, Mr. Naveen Kumar, Group CEO of Napino, said; “Zero emission mobility has become a global movement & with Enedym as our partner, we are gearing up to meet the current & future requirements of electric mobility. As a technology driven organization, Napino has constantly reinforced its position as a leading Auto Electronics System Supplier, offering innovative, sustainable and robust solutions for its customers. Working on cutting-edge technologies ensures that we continue to be at the forefront of the rapidly transforming business landscape.”
Sumit Dhanuka, Founder & Managing Partner of Precog Innovation Partners, commented, "We are excited to have enabled this unique strategic partnership between Napino and Enedym. This collaboration brings together Enedym’s cutting-edge design and development capabilities in the SRM motor technology space and Napino’s strong automotive manufacturing and go-to-market strengths in the Indian market, helping us realize the shared vision towards Net-Zero Mobility and an Aatmanirbhar Bharat (Self-reliant India).”
Enedym recently announced a $15 million financing round from an international group of strategic investors within the U.S., Canada, Europe, and India.
About Enedym, Inc.
Enedym is a technology start-up company from McMaster University. The company is headquartered at the McMaster Innovation Park in Hamilton, Ontario, Canada. Enedym has ownership of over 50 patents and pending patent applications and related inventions developed by the Canada Excellence Research Chair in Hybrid Powertrain Dr. Ali Emadi and his research group at the McMaster Automotive Resource Centre (MARC), McMaster University. Enedym’s vision is to reduce the cost of electric propulsion motors significantly and power a new paradigm in the electric motor industry through novel switched reluctance motor (SRM) drive technologies. Enedym aspires to help save the planet, one electric motor market at a time. To learn more about Enedym, please visit www.enedym.com and our YouTube channel at Enedym YouTube .
Napino Auto & Electronics Ltd
Napino is one of India's leading supplier of automotive electronic products. It employs roughly 6000 employees. The portfolio includes ECUs, capacitor-discharge ignitor, regulator rectifier, wiring harness, handlebar switches, and E Mobility products among other electronic offerings. As a leader in its segment with complete design, development, and manufacturing capabilities, Napino offers innovative solutions to major automobile manufacturers. Through its robust R&D capabilities and sustainable partnerships with global players, Napino aspires to lead technology innovation in automotive electronics. To learn more, please visit http://napino.com
View source version on businesswire.com: https://www.businesswire.com/news/home/20210825005029/en/
Link:
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Galderma Receives U.S. FDA Approval for Differin® Epiduo® Acne Gel Prescription-to-OTC Switch22.5.2026 18:25:00 CEST | Press release
A unique Prescription-to-OTC switch in acne care, this approval expands access to a dermatologist-trusted, prescription-strength treatment for millions of acne sufferers ages 12 years and older Backed by more than 15 years of real-world dermatologist use and a robust clinical research program, this milestone demonstrates the depth of science behind the Differin® and Epiduo® heritage Adapalene plus benzoyl peroxide (0.1/2.5%) was the first FDA-approved, stable, fixed- dose prescription acne treatment to combine of benzoyl peroxide with a retinoid, and is now available over-the-counter The formulation is engineered to target multiple causes of acne more effectively than either of its individual active ingredients alone Galderma (SIX: GALD), the pure-play dermatology category leader, today announced that the United States (U.S.) Food and Drug Administration (FDA) has approved Differin® Epiduo® Acne Gel (Adapalene 0.1% and Benzoyl Peroxide 2.5% Acne Treatment) for over-the-counter (OTC) us
Avanzanite Bioscience’s Partner Agios Announces PYRUKYND® (mitapivat) Approval in the European Union for Adults with Thalassaemia22.5.2026 16:18:00 CEST | Press release
Avanzanite will commercialise and distribute PYRUKYND in Europe under its exclusive agreement with Agios Avanzanite is committed to collaborating with local authorities in the EU to enable access to PYRUKYND for adult patients with thalassaemia Avanzanite Bioscience B.V., a rapidly growing commercial-stage European specialty pharmaceutical company focused on rare diseases, today reported that its partner, Agios Pharmaceuticals, Inc. (Nasdaq: AGIO), a commercial-stage biopharmaceutical company headquartered in Cambridge, Massachusetts focused on delivering innovative medicines for patients with rare diseases, announced that the European Commission has granted marketing authorisation for PYRUKYND® (mitapivat), an oral pyruvate kinase (PK) activator, in adults for the treatment of anaemia associated with transfusion-dependent and non-transfusion-dependent alpha- or beta-thalassaemia, with an orphan medicinal product designation. This press release features multimedia. View the full releas
ICE Brent and ICE WTI Perpetual Futures to Launch on OKX22.5.2026 14:30:00 CEST | Press release
OKX, a blockchain technology and trading company serving more than 120 million customers globally,and Intercontinental Exchange (NYSE: ICE), one of the world's leading providers of financial market technology and data powering global capital markets including the New York Stock Exchange, today announced plans for OKX to launch perpetual futures based on ICE's Brent Crude and WTI Crude energy benchmarks. The products are expected to be available to trade on OKX’s platform in jurisdictions where OKX is licensed to offer perpetual futures products. The new OKX contracts represent a major step forward in expanding regulated access to global commodity markets through digital asset infrastructure. This first product collaboration between OKX and ICE comes after the companies established a strategic relationship in March 2026. ICE operates some of the world’s leading exchanges, clearing houses and market data services across energy, commodities, fixed income and equities markets. ICE’s future
Enhertu® Recommended for Approval in the EU by CHMP for Patients with Previously Treated HER2 Positive Metastatic Solid Tumors22.5.2026 14:00:00 CEST | Press release
Enhertu® (trastuzumab deruxtecan) has been recommended for approval in the European Union (EU) as a monotherapy for the treatment of adult patients with unresectable or metastatic HER2 positive (immunohistochemistry [IHC] 3+) solid tumors who have received prior treatment and who have no satisfactory treatment options. Enhertu is a specifically engineered HER2 directed DXd antibody drug conjugate (ADC) discovered by Daiichi Sankyo (TSE: 4568) and being jointly developed and commercialized by Daiichi Sankyo and AstraZeneca (LSE/STO/NYSE: AZN). The Committee for Medicinal Products for Human Use (CHMP) of the European Medicines Agency (EMA) based its positive opinion on results from patients with HER2 positive (IHC 3+) tumors in three phase 2 trials including DESTINY-PanTumor02,DESTINY-Lung01 andDESTINY-CRC02 where Enhertu demonstrated clinically meaningful responses across a broad range of tumors. The recommendation will now be reviewed by the European Commission, which has the authority
Future Health Challenge Awards USD 300,000 to Early Detection and Population Health Sensing Tools on Sidelines of World Health Assembly22.5.2026 13:45:00 CEST | Press release
Global teams recognised in the Future Health Challenge for solutions designed to detect health risks earlier and support faster health system decisions Future Health – A Global Initiative by Abu Dhabi and MIT Solve announce the winners of the inaugural Future Health ChallengeWinning solution equips frontline health workers in low-resource settings with mobile clinical decision-support tools, enabling earlier detection and more effective care deliveryTeams competed for a USD 200,000 grand prize and two USD 50,000 runner-up awards on the sidelines of the 79th World Health Assembly in GenevaWinners recognised for solutions advancing anticipatory, data-driven health systems Three global teams developing early detection and real-time population health monitoring solutions have secured a total of USD 300,000 on the sidelines of the 79th World Health Assembly. The winning solutions address critical challenges in early detection, continuous population insight and more timely decision making, s
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom